Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T22:22:15.904Z.
Calculation as of: 2026-10-06T22:22:15.904Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a84589f7b73c5fc7448e1a11526b61c4e763dd9c6e5f877a8586f943b51ec8b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Inovio Pharmaceuticals, Inc.
Market Cap
$78.07M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$77.54M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$79.03M
Price/OCF Ratio
N/A
TTM Avg
786.57
3Y Avg
786.57
5Y Avg
786.57
Market Cap
$79.61M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$75.95M
Price/OCF Ratio
3.46
TTM Avg
3.93
3Y Avg
19.17
5Y Avg
19.17
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inovio Pharmaceuticals, Inc. (INO) | $78.07M | N/A | N/A | N/A | N/A |
| Sera Prognostics, Inc. (SERA)vs › | $78.29M | N/A | N/A | N/A | N/A |
| vTv Therapeutics Inc. (VTVT)vs › | $78.59M | N/A | N/A | N/A | N/A |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $77.54M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $79.03M | N/A | 786.57 | 786.57 | 786.57 |
| Outset Medical, Inc. (OM)vs › | $76.74M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | N/A | N/A | N/A | N/A |
| SkinHealth Systems Inc. (SKIN)vs › | $75.95M | 3.46 | 3.93 | 19.17 | 19.17 |
| Humacyte, Inc. (HUMA)vs › | $80.30M | N/A | N/A | N/A | N/A |
| Pulmonx Corporation (LUNG)vs › | $75.18M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
